Drug Profile
Research programme: eye disorders therapies - CombinatoRx/Fovea
Alternative Names: FOV 2301Latest Information Update: 19 Feb 2010
Price :
$50
*
At a glance
- Originator CombinatoRx; Fovea Pharmaceuticals
- Developer Fovea Pharmaceuticals
- Class
- Mechanism of Action Steroid receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Diabetic macular oedema
Most Recent Events
- 09 Nov 2007 Preclinical trials in Diabetic macular oedema in France (Intravitreous)
- 20 Feb 2006 Preclinical trials in Eye disorders in France (unspecified route)